Michael Silverberg to HIV Protease Inhibitors
This is a "connection" page, showing publications Michael Silverberg has written about HIV Protease Inhibitors.
Connection Strength
0.633
-
Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus. Pharmacotherapy. 2011 Mar; 31(3):253-61.
Score: 0.377
-
Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020 04; 23(4):e25484.
Score: 0.177
-
Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):393-398.
Score: 0.060
-
Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
Score: 0.020